Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Harnisch, P. Chanu, K. Dykstra, L. Claret, R. Bruno, X. Gao (Sandwich, United Kingdom; St. Louis, New London, United States Of America). Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil. Eur Respir J 2010; 36: Suppl. 54, 200

Member's Comments

No comment yet.

Related content which might interest you: Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension Source: Eur Respir J 2013; 42: 414-424 Year: 2013 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Exercise tolerability in children with pulmonary arterial hypertension (PAH), a population pk/pd assessment of the effects of sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effect of treatment on exercise endurance tolerance and ventilatory efficiency in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Value of maximal and submaximal variables during incremental cardiopulmonary exercise testing to predict survival in pateints with pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Impact of 3-months COVID-19 lockdown on exercise capacity in stable pulmonary arterial hypertension Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 The value of cardiopulmonary exercise test in assessment of the severity of pulmonary arterial hypertension patients Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Mobile spiroergometry for prediction of survival in pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Hemodynamic correlates of exercise capacity in patients with pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 17s Year: 2005